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ABSTRACT
Objective To validate a mathematical algorithm that
calculates risk of diabetic retinopathy progression in a
diabetic population with UK staging (R0–3; M1) of
diabetic retinopathy. To establish the utility of the
algorithm to reduce screening frequency in this cohort,
while maintaining safety standards.
Research design and methods The cohort of 9690
diabetic individuals in England, followed for 2 years. The
algorithms calculated individual risk for development of
preproliferative retinopathy (R2), active proliferative
retinopathy (R3A) and diabetic maculopathy (M1) based
on clinical data. Screening intervals were determined
such that the increase in risk of developing certain
stages of retinopathy between screenings was the same
for all patients and identical to mean risk in ﬁxed annual
screening. Receiver operating characteristic curves were
drawn and area under the curve calculated to estimate
the prediction capability.
Results The algorithm predicts the occurrence of the
given diabetic retinopathy stages with area under the
curve =80% for patients with type II diabetes (CI 0.78
to 0.81). Of the cohort 64% is at less than 5% risk of
progression to R2, R3A or M1 within 2 years. By
applying a 2 year ceiling to the screening interval,
patients with type II diabetes are screened on average
every 20 months, which is a 40% reduction in frequency
compared with annual screening.
Conclusions The algorithm reliably identiﬁes patients
at high risk of developing advanced stages of diabetic
retinopathy, including preproliferative R2, active
proliferative R3A and maculopathy M1. Majority of
patients have less than 5% risk of progression between
stages within a year and a small high-risk group is
identiﬁed. Screening visit frequency and presumably costs
in a diabetic retinopathy screening system can be
reduced by 40% by using a 2 year ceiling. Individualised
risk assessment with 2 year ceiling on screening intervals
may be a pragmatic next step in diabetic retinopathy
screening in UK, in that safety is maximised and cost
reduced by about 40%.
INTRODUCTION
The overall objective of this work is to use informa-
tion technology and individual risk assessment by
mathematical algorithms to increase the efﬁcacy of
screening systems in medicine. The speciﬁc case is
diabetic retinopathy screening, which has been suc-
cessful in reducing diabetic blindness in many
countries1 2 but may provide opportunity for
improved cost-effectiveness.
Initially annual screening for diabetic retinopathy
was the rule and is still recommended by WHO
and many professional societies and practised in
many countries, including the UK. However, more
and more evidence has shown that annual screening
is an overkill for low-risk patients with diabetes.
Kristinsson et al,3 showed that diabetics without
retinopathy may safely be screened every other year
and this was conﬁrmed by a 10 year experience.4
Biennial screening is practiced in many screening
programmes for diabetic retinopathy and simple
risk stratiﬁcation has been explored.5 6
More recently, we proposed to use individual
multifactor risk assessment for diabetic retinopathy
progression to control screening frequency and
further economise screening programmes for dia-
betic retinopathy. Aspelund et al7 developed a math-
ematical algorithm that calculates individual risk for
progression to sight-threatening diabetic retinopathy
and can be used to control the frequency of diabetic
eye-screening visits. The algorithm receives clinical
data: type and duration of diabetes, HbA1c, systolic
blood pressure, gender and the presence and grade
of retinopathy. These data are used to calculate an
individual’s risk of developing sight-threatening ret-
inopathy (STR), that is, proliferative diabetic retin-
opathy and/or clinically signiﬁcant diabetic macular
oedema. This algorithm has been validated success-
fully in Denmark,7 the Netherlands8 and Spain.9 It
predicts about 80% of the risk of progression of dia-
betic retinopathy and recommends a screening inter-
val according to individual risk. This allows
reduction in mean screening frequency by over 50%
(depending on interval ceiling) with corresponding
reduction in costs. At the same time, high-risk
patients with diabetes are screened more frequently,
up to every 6 months depending on individual risk.
There is a slight difference in staging of diabetic
retinopathy in the Danish, Dutch, Spanish and
Icelandic cohorts initially used to calibrate the algo-
rithm and the English screening system, which uses
R0–3 with the subdivision of the third R3A (active
proliferation) and R3AS (stable proliferation). M1
describes maculopathy in accordance with the
English National Diabetic Eye Screening Program
deﬁnition. (http://diabeticeye.screening.nhs.uk/getdata.
php?id=11653). In order to use the algorithm in
the English screening system, it must be calibrated
for this staging and preferably in an English dia-
betic cohort.
The aim of this analysis is threefold: First to inves-
tigate whether the algorithm can be used to predict
the risk of R2 (preproliferative retinopathy), R3A
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(active proliferative retinopathy) and M1 (diabetic maculopathy).
We also want to estimate the possible reduction in screening fre-
quency in this cohort, while maintaining safety standards. The
third goal is to establish the risk proﬁle for the cohort to recog-
nise how many are at low risk and how many have high risk for
progression within 2 years.
METHODS
This study is based on data of 9690 individuals with diabetes in
England who are participating in the English National Diabetes
Eye Screening Programme. Data was made available on research
consented patients, and their anonymised data included their
retinopathy stage in the R and M scales annually for 3 years.
Clinical data was also available on type and duration of diabetes,
HbA1c, systolic blood pressure, gender and the presence and
grade of retinopathy. Three individuals with systolic blood pres-
sure less than 80 mm Hg were excluded from the analysis.
Based on the algorithm of Aspelund et al,7 the subjects’ risk of
developing R2, R3A or M1 was calculated and screening inter-
vals were recommended. The calculations were done using clin-
ical data gathered in the year 2010 and compared with clinical
outcome in the year 2012.
The algorithm was originally designed to estimate the risk of
developing sight-threatening retinopathy (STR, either diabetic
macular edema (DME) or proﬁlerative diabetic retinopathy
(PDR)). In order to predict the risk of the occurrence of retinop-
athy stage R2, R3A or M1, instead of STR), a calibration coefﬁ-
cient was calculated for each retinopathy stage, and gender and
type of diabetes. The coefﬁcient was the observed proportion of
each outcome divided by the average risk estimate for STR. An
estimate of the risk of developing R2, R3A or M1 was calculated
by multiplying the risk estimate of the algorithm with the corre-
sponding calibration coefﬁcient.
The recommended screening intervals were calculated so that
the average cumulative risk of developing R2, R3A or M1
within the screening period was kept identical to the cumulative
incidences of the corresponding retinopathy grading that were
observed with annual screening.
A receiver operating characteristic (ROC) curve is a plot of
the true positive rate (sensitivity) against the false positive rate
(1−speciﬁcity) for the different decision thresholds of a diagnos-
tic test.10 The area under the ROC curve is an estimate of the
capacity of the diagnostic test to distinguish individuals with
versus those without disease. It can range from 0.5 to 1, where
an area of 1 represents a perfect test and an area of 0.5 repre-
sents a worthless test. ROC curves were plotted for the ability
of the algorithm to predict development of R2, R3A and M1
within 2 years for the population in total as well as patients
with type I and type II diabetes separately. ROC curves for the
ability of any retinopathy grading were also drawn for patients
with type I and type II diabetes separately.
RESULTS
Diagnostic capacity of the algorithm
The number of men and women who developed R2, R3A, M1
or any of R2, R3A or M1 within a year or within 2 years, is
shown in table 1. The results are split up by gender and the
type of diabetes.
In order to investigate the ability of the algorithm to predict
R2, R3A and M1, 2 years risk was calculated for every individ-
ual in the sample and compared with the actual outcome
2 years later. Figure 1A–D shows ROC curves for predicting R2,
R3A or M1 based on the 2 year risk estimates. (A) for the total
population (B) for patients with type I diabetes only (C) for
patients with type II diabetes only (D) any retinopathy grading
(any of the criteria, R2, and R3A and M1) for patients with
type I and type II diabetes separately.
Risk distribution of the population
Risk of R2, R3A and M1 was estimated using the risk algorithm
adapted to 2 years. The risk score was calibrated to the type of
events by multiplying with the ratio of observed number of
events. The bar graph in ﬁgure 2A–D shows the frequency dis-
tribution of the estimated risk of the population. The risk has
been categorised into three groups, 0–5%, 5–10% and above
10% and the height of the bars represent the number of indivi-
duals with the corresponding risk. Figure 2A shows the risk of
developing R2 within 2 years, ﬁgure 2B shows risk of develop-
ing R3A, ﬁgure 2C shows the risk of developing M1 and ﬁnally
ﬁgure 2D shows the risk of developing any of R2, R3A or M1.
Screening interval recommendations
The observed 1 year frequency of each of the retinopathy
grading (R2, R3A and M1) was calculated for sex and type of
diabetes separately. For every individual, the recommended
screening interval was set at the time period over which the risk
of developing R2, R3A or M1 would be identical to the mean
annual incidence within the cohort. The annual incidence for
each group was shown in table 1. Table 2 shows the mean
screening intervals of the patients by the type of diabetes and
whether they developed R2, R3A or M1 within 2 years or not.
The results are shown for intervals with a 6 months ﬂoor and a
24 months ceiling.
DISCUSSION
The mathematical algorithm reliably predicts progression of dia-
betic retinopathy in the English cohort, as it did previously in
Danish,7 Dutch8 and Spanish cohorts.9 It identiﬁes a relatively
small group of high-risk patients based on clinical data, who
need frequent screening, while a much larger group at low risk
is well served with less frequent screening, which may reduce
costs for health systems and patients alike.
The system, if used in conjunction with a live data feed from
clinical systems, can automatically adjust to a change in
Table 1 Number and incidence (%) of individuals who develop R2
(preproliferative retinopathy), R3A (active proliferative retinopathy),
M1 (diabetic maculopathy) or any of R2, R3A or M1, split up by sex
and type of diabetes
Type I Type II
Men (%) 252 (51.9) 5211 (56.6)
Total (%) 486 (5.0) 9201 (95.0)
annual biennial annual biennial
Men
Developed R2 (%) 22 (8.7) 35 (13.9) 69 (1.3) 110 (2.1)
Developed R3A (%) 15 (6.0) 17 (6.7) 25 (0.5) 45 (0.9)
Developed M1 (%) 23 (9.1) 36 (14.3) 114 (2.2) 216 (4.1)
Developed any above (%) 41 (16.3) 52 (20.6) 153 (2.9) 259 (5.0)
Women
Developed R2 (%) 15 (6.4) 23 (9.8) 32 (0.8) 56 (1.4)
Developed R3A (%) 11 (4.7) 14 (6.0) 9 (0.2) 14 (0.4)
Developed M1 (%) 17 (7.3) 31 (13.2) 89 (2.2) 153 (3.8)
Developed any above (%) 30 (12.8) 41 (17.5) 107 (2.7) 179 (4.5)
The results are shown for annual incidence (1 year) and biennial incidence (2 years).
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circumstances of the patient such as a change of medication or
lifestyle that is likely to affect prognosis. It can also add other
validated risk factors such as microaneurysm turnover to pos-
sibly predict outcomes even more accurately.
The risk estimates can serve as a basis to classify patients into
low risk, medium risk and high risk, that is, patients with lower
than 5% annual risk of any progression can be classiﬁed as low
risk, whereas patients with 5–10% risk would be classiﬁed as
medium and patients with greater than 10% annual risk would
be classiﬁed as high risk. In countries with limited healthcare
resources, this approach may be used to prioritise patients for
diabetic eye screening.
For patients with type II diabetes, the area under the curve is
0.80 for the prediction model for the risk of developing R2,
R3A or M1. This indicates that there is 80% probability that a
randomly selected patient that develops background retinopathy
will be given a higher risk score and therefore a shorter screen-
ing interval than a patient that does not develop R2, R3A or
M1. The ROC curves and risk prediction seems very reliable for
patients with type II diabetes, but with the lower numbers of
patients with type I diabetes, there is more variability in the out-
comes in this group. The patients with type I diabetes are only
about 5% of the total cohort. This is lower than the UK average
of about 10% (https://www.diabetes.org.uk/documents/reports/
diabetes_in_the_uk_2010.pdf).11 The analysis in the type II
cohort may be seen as more robust and it may be wise to imple-
ment this algorithm initially in patients with type II diabetes.
By applying a 6 months ﬂoor and a 24 months ceiling, the
screening frequency can be reduced by 40% for patients with
type II diabetes without compromising safety. Lowering the
risk margin such that the average screening interval of
patients that develop R2, R3A or M1 is unchanged at
12 months, leads to 36% reduction in screening visits and
presumably also cost.
McGhee et al12 discuss the applicability of our algorithm in
diabetic retinopathy screening and potential pitfalls. They point
out that a 5 years ceiling for intervals in screening, which is pro-
posed as one possibility in our earlier reports,7 may be danger-
ously long because patients’ clinical risk factors may change
during this long period. This is true and for a 3–5 years screen-
ing interval to succeed, recalculation of risk would need to take
place in the diabetes or general practice clinic during the inter-
val. It may be most practical to use a 2 years ceiling on the
screening interval, at least in the beginning. This approach
increases the mean screening interval in patients with type II
diabetes from 12 months to 20 months, which is 40% reduction
Figure 1 (A) ROC (receiver operating characteristic) curves for predicting R2 (preproliferative retinopathy), R3A (active proliferative retinopathy)
or M1 (diabetic maculopathy), based on the risk estimates of the algorithm. Patients with type I and type II diabetes together. Curves for R2 are
coloured in blue, R3A in green and M1 in red. The AUC (area under curve) was: R2: 0.81 (CI 0.79 to 0.83), R3A: 0.78 (CI 0.75 to 0.81), M1: 0.79
(CI 0.77 to 0.80). (B) ROC curves for predicting R2, R3A or M1, based on the risk estimates of the algorithm. Patients with type I diabetes only.
Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC was: R2: 0.72 (CI 0.69 to 0.76), R3A: 0.74 (CI 0.69 to 0.79), M1: 0.68
(CI 0.64 to 0.71). (C) ROC curves for risk predicting of R2, R3A or M1 based on the risk estimates of the algorithm. Patients with type II diabetes
only. Curves for R2 are coloured in blue, R3A in green and M1 in red. The AUC was: R2: 0.83 (CI 0.81 to 0.84), R3A: 0.80 (CI 0.76 to 0.83), M1:
0.79 (CI 0.78 to 0.81). (D) ROC curves for predicting any of R2, R3A or M1 based on the risk estimates of the algorithm. Coloured in blue are
patients with type II diabetes, and patients with type I diabetes are shown in red. The AUC is 70% for patients with type I diabetes (CI 0.67 to
0.73) and 80% for patients with type II diabetes (CI 0.78 to 0.81).
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in screening frequency. This is a very substantial cost reduction
and avoids the potential difﬁculties of longer intervals. Biennial
screening has long safety record in Iceland and Sweden.4 Similar
success with extended screening intervals has been reported in
the UK.13
In countries with limited clinical and ﬁnancial resources,
the algorithm may be used to identify high-risk patients with
diabetes and prioritise who gets access to retinopathy screen-
ing and possibly bring to light the need for other appropriate
health interventions. This may help deal with the conse-
quences of the global epidemic of diabetes mellitus. To date
the algorithm has been validated in mostly Caucasian
European countries. Validation in other ethnic groups and
countries is needed for the global application of this
approach.
Individualised risk assessment inherently increases individual
patient safety. High-risk patients are reliably identiﬁed and
screening intervals shortened appropriately. It is possible to
introduce whatever safety margin is desired and is economically
feasible; a live feed of clinical data will also assist in reducing
risk. There is greater risk in treating all patients with diabetes as
equal (in terms of risk of progression), for outliers in the group
are likely to suffer from management parameters aimed at the
average risk level.
Figure 2 (A) Distribution of the estimated adjusted risk of developing R2 (preproliferative retinopathy) within 2 years according to the algorithm.
The height of the bar represents the number of individuals that fall within the corresponding risk group. Within 2 years, 8286 had 0–5% risk, 747
had 5–10% and 654 had 10–30% risk of developing R2. (B) Distribution of the estimated adjusted risk of developing R3A (proliferative diabetic
retinopathy) within 2 years according to the algorithm. The height of the bar represents the number of individuals that fall within the corresponding
risk group. Within 2 years, 9150 had 0–5% risk, 258 had 5–10% and 279 had 10–30% risk of developing R3A. (C) Distribution of the estimated
adjusted risk of developing M1 (diabetic macular oedema) within 2 years according to the algorithm. The height of the bar represents the number of
individuals that fall within the corresponding risk group. Within 2 years 6728 had 0–5% risk, 1506 had 5–10% and 1453 had 10–30% risk of
developing M1. (D) Distribution of the estimated adjusted risk of developing any of R2 (moderate or severe preproliferative retinopathy), R3A
(proliferative retinopathy) or M1 (diabetic maculopathy) within 2 years according to the algorithm. The height of the bar represents the number of
individuals that fall within the corresponding risk group. Within 2 years 6207 had 0–5% risk, 1666 had 5–10% and 1814 had 10–30% risk of
developing R2, R3A or M1.
Table 2 Average recommended screening intervals by type of
diabetes in individuals who either developed R2 (preproliferative
retinopathy), R3A (active proliferative retinopathy) or M1 (diabetic
maculopathy) within 2 years or not
Average screening
interval (months)
Reduction in
screening
frequency (%)Regime
Without R2,
R3 or M1
With R2,
R3, or M1
Type I 2 years ceiling 23.7 22.7 48.9
Type II 2 years ceiling 20.3 13.5 40.0
The results are shown for intervals with a 6 months floor and a 24 months ceiling.
The last column shows the resulting reduction in the annual number of screenings of
the population when applying the corresponding screening regime. With a 2 years
ceiling, the mean recommended screening interval is 13.5 months for the patients
with type II diabetes who develop R2, R3A or M1 within 2 years and 20.3 months for
those who do not. The overall reduction in screening frequency in patients with type
II diabetes is 40%.
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CONCLUSION
The algorithm reliably predicts the risk of progression of dia-
betic retinopathy to R2, R3A and M1.
Validation studies of the cohort in Danish, Dutch, Spanish
and now English cohorts give similar results.
Risk proﬁles for the cohort show that a great majority is at
less than 3.4% risk of progression between stages in 1 year. A
small high-risk group is identiﬁed.
With standard average risk for progression at next visit, the
mean screening interval for patients with type II diabetes can be
extended from 12 months to 20 months with 40% reduction in
frequency and costs.
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